File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Article: Update on photodynamic therapy with verteporfin for macular diseases

TitleUpdate on photodynamic therapy with verteporfin for macular diseases
Authors
KeywordsChoroidal neovascularization
Macula
Photodynamic therapy
Issue Date2004
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.cohk.org.hk/journals.php
Citation
Hong Kong Journal of Ophthalmology, 2004, v. 8 n. 1, p. 23-35 How to Cite?
AbstractChoroidal neovascularization in the macula is a major cause of visual disability in developed countries. Age-related macular degeneration is one of the commonest underlying etiologies for choroidal neovascularization, while other conditions include pathologic myopia, idiopathic, postchoroiditis, iatrogenic, and other causes. There have been no good and safe treatments for choroidal neovascularization at subfoveal areas. Photodynamic therapy with verteporfin has been shown to be effective in reducing the likelihood of visual loss due to choroidal neovascularization in age-related macular degeneration, especially when the lesion has predominantly classic composition. Further evidence indicates the beneficial effects in agerelated macular degeneration with progressive occult choroidal neovascularization of small size and also in subfoveal choroidal neovascularization of pathologic myopia. The indications and applications of photodynamic therapy have been expanding swiftly and this treatment modality may provide a new hope for diseases such as polypoidal choroidal vasculopathy and central serous chorioretinopathy, which are more prevalent in Asian populations.
Persistent Identifierhttp://hdl.handle.net/10722/206200
ISSN

 

DC FieldValueLanguage
dc.contributor.authorChan, WM-
dc.contributor.authorLiu, DTL-
dc.contributor.authorLai, TYY-
dc.contributor.authorLi, KKW-
dc.contributor.authorLee, VYW-
dc.contributor.authorTsang, CW-
dc.contributor.authorLai, WWK-
dc.contributor.authorLau, HHK-
dc.contributor.authorTang, EWH-
dc.contributor.authorMohamed, S-
dc.contributor.authorLim, E-
dc.contributor.authorLam, DSC-
dc.date.accessioned2014-10-21T03:27:56Z-
dc.date.available2014-10-21T03:27:56Z-
dc.date.issued2004-
dc.identifier.citationHong Kong Journal of Ophthalmology, 2004, v. 8 n. 1, p. 23-35-
dc.identifier.issn1027-8230-
dc.identifier.urihttp://hdl.handle.net/10722/206200-
dc.description.abstractChoroidal neovascularization in the macula is a major cause of visual disability in developed countries. Age-related macular degeneration is one of the commonest underlying etiologies for choroidal neovascularization, while other conditions include pathologic myopia, idiopathic, postchoroiditis, iatrogenic, and other causes. There have been no good and safe treatments for choroidal neovascularization at subfoveal areas. Photodynamic therapy with verteporfin has been shown to be effective in reducing the likelihood of visual loss due to choroidal neovascularization in age-related macular degeneration, especially when the lesion has predominantly classic composition. Further evidence indicates the beneficial effects in agerelated macular degeneration with progressive occult choroidal neovascularization of small size and also in subfoveal choroidal neovascularization of pathologic myopia. The indications and applications of photodynamic therapy have been expanding swiftly and this treatment modality may provide a new hope for diseases such as polypoidal choroidal vasculopathy and central serous chorioretinopathy, which are more prevalent in Asian populations.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.cohk.org.hk/journals.php-
dc.relation.ispartofHong Kong Journal of Ophthalmology-
dc.rightsHong Kong Journal of Ophthalmology. Copyright © Hong Kong Academy of Medicine Press.-
dc.subjectChoroidal neovascularization-
dc.subjectMacula-
dc.subjectPhotodynamic therapy-
dc.titleUpdate on photodynamic therapy with verteporfin for macular diseasesen_US
dc.typeArticleen_US
dc.identifier.emailLi, KKW: kenkwli@hkucc.hku.hk-
dc.identifier.emailLai, WWK: wicolai@hku.hk-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.hkuros164017-
dc.identifier.volume8-
dc.identifier.issue1-
dc.identifier.spage23-
dc.identifier.epage35-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats